

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**中生北控生物科技股份有限公司**  
**BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION**

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 8247)**

**(I) POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON 28 JUNE 2024;**  
**(II) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;  
AND**  
**(III) CHANGE OF SUPERVISOR**

**POLL RESULTS OF THE AGM**

The Board is pleased to announce that all resolutions as set out in the Notice dated 6 June 2024 and the Supplemental Notice dated 18 June 2024 were duly passed by way of poll by the Shareholders at the AGM held on Friday, 28 June 2024.

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board also announces that Dr. He Xin has been appointed as an independent non-executive Director with effect from 28 June 2024 following the approval of her appointment by the Shareholders at the AGM.

The Board further announces that following the appointment of Dr. He Xin as an independent non-executive Director, she has also been appointed as a member of each of the Audit Committee, the Nomination Committee and the Remuneration Committee with effect from 28 June 2024.

**CHANGE OF SUPERVISOR**

The Board also announces that Mr. Fan Hua has been appointed to replace Mr. Li Jifeng as a Supervisor with effect from 28 June 2024 following the approval of his appointment by the Shareholders at the AGM. Upon his appointment as a Supervisor, Mr. Fan Hua will also act as the chairman of the Supervisory Committee.

References are made to (i) the announcement of Biosino Bio-Technology and Science Incorporation (the “**Company**”) dated 26 April 2024 (the “**Resignation Announcement**”) in relation to the resignation of Mr. Li Jifeng (李繼峰) (“**Mr. Li**”) as a shareholder representative supervisor of the Company (the “**Supervisor(s)**”) and the chairman of the supervisory committee of the Company (the “**Supervisory Committee**”); (ii) the announcement of the Company dated 12 June 2024 (the “**Appointments Announcement**”) in relation to the proposed appointments of Dr. He Xin (何欣) (“**Dr. He**”) as an independent non-executive Director and Mr. Fan Hua (范華) (“**Mr. Fan**”) as a Supervisor; (iii) the notice (the “**Notice**”) of the annual general meeting (the “**AGM**”) dated 6 June 2024 and the supplemental notice (the “**Supplemental Notice**”) of the AGM dated 18 June 2024 of the Company; and (iv) the circular (the “**Circular**”) of the Company dated 6 June 2024 and the supplemental circular (the “**Supplemental Circular**”) of the Company dated 18 June 2024. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Resignation Announcement, the Appointments Announcement, the Circular and the Supplemental Circular (as the case may be).

### (I) POLL RESULTS OF THE AGM

The AGM was held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC on Friday, 28 June 2024. The Board is pleased to announce that all resolutions as set out in the Notice and the Supplemental Notice were duly passed at the AGM. As at the date of the AGM, the Company issued a total of 144,707,176 Shares, comprising 64,286,143 H Shares and 80,421,033 Domestic Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against the resolutions proposed at the AGM. There were no Shares entitling the holders thereof to attend and vote only against the resolutions at the AGM. No restriction was imposed on any Shareholder casting votes on any of the proposed resolutions at the AGM. All the resolutions at the AGM were put to the vote by way of poll. BDO China Shu Lun Pan Certified Public Accountants LLP was appointed as the scrutineer at the AGM for the purpose of vote-taking.

The poll results of the respective resolutions at the AGM are as follows:

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To consider and approve the report of the Board for the year ended 31 December 2023.	105,617,000 (100%)**	0 (0%)**
2.	To consider and approve the report of the supervisory committee of the Company for the year ended 31 December 2023.	105,617,000 (100%)**	0 (0%)**
3.	To consider and approve the audited consolidated financial statements of the Company and its subsidiaries and the independent auditors’ report for the year ended 31 December 2023.	105,617,000 (100%)**	0 (0%)**

<b>ORDINARY RESOLUTIONS</b>		<b>Number of votes cast and approximate percentage of total number of votes cast</b>	
		<b>For</b>	<b>Against</b>
4.	To consider and approve the 2023 annual final financial report and the 2024 financial budget report of the Company.	105,617,000 (100%)**	0 (0%)**
5.	To consider and approve the re-appointment of Ernst & Young Hua Ming as the PRC auditors and Ernst & Young as the international auditors of the Company to hold office until the conclusion of the next AGM and to authorise the Board to fix their remuneration.	105,617,000 (100%)**	0 (0%)**
5A.	To consider and approve the appointment of Dr. He Xin as an independent non-executive Director, and authorise the Board to fix her remuneration and to enter into service contract with her subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters.	105,617,000 (100%)**	0 (0%)**
5B.	To consider and approve the appointment of Mr. Fan Hua as a Supervisor and authorise the Board to fix his remuneration and to enter into service contract with him subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters.	105,617,000 (100%)**	0 (0%)**
<b>SPECIAL RESOLUTIONS</b>			
6.	To give a general mandate to the Board to issue, allot and deal with additional Shares not exceeding 20% of the Shares in issue.	74,308,424 (70.36%)**	31,308,576 (29.64%)**
7.	To consider and approve the proposed amendments to the Articles of Association.	105,617,000 (100%)**	0 (0%)**

\*\* *The percentage of voting Shares is based on the total number of Shares held by the Shareholders who voted at the AGM in person or by proxy.*

As more than 50% of the total number of Shares held by the Shareholders who voted at the AGM were cast in favour of each of the resolution nos. (1) to (5B) and more than two-thirds of the total number of Shares held by the Shareholders who voted at the AGM were cast in favour of resolution nos. (6) and (7), all the above resolutions were approved by the Shareholders.

Mr. Wu Lebin, Mr. Yang Peng, Mr. Chen Zhengyong, Mr. Chen Peng, Mr. Li Zhonghua, Dr. Gao Guangxia, Prof. Shen Zuojun and Mr. Lu Qi attended the AGM either in person or by electronic means, whereas Prof. Shen Jiangang was unable to attend the AGM due to other business commitments.

## (II) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board also announces that Dr. He has been appointed as an independent non-executive Director with effect from 28 June 2024 following the approval of her appointment by the Shareholders at the AGM.

The Board further announces that following the appointment of Dr. He as an independent non-executive Director, she has also been appointed as a member of each of the Audit Committee, the Nomination Committee and the Remuneration Committee with effect from 28 June 2024.

Dr. He has confirmed that (i) she met the independence criteria as set out in Rule 5.09 of the GEM Listing Rules; (ii) she has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the GEM Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

Biographical details of Dr. He are as follows:

**Dr. He Xin (何欣博士)**, aged 52, obtained a Doctor of Philosophy in Immunobiology from Yale University in 2003. She has more than 20 years of experience in healthcare enterprise operations, international business development and investment. Dr. He was the founder and the chief executive officer of RHEI Pharmaceuticals, Inc., which is a fully integrated specialty pharmaceuticals company. She was also a partner of Columbus Growth, LLC and a senior partner of Beijing Dinghui Innovative Investment Consultant Co. Ltd.\* (北京鼎暉創新投資顧問有限公司). Dr. He is currently a managing partner of Ningbo Huiding Cornerstone Investment Management Co. Ltd.\* (寧波匯鼎基石投資管理有限公司).

Dr. He will enter into a service agreement with the Company. Her term of service with the Company takes effect from the date of approval by the Shareholders at the AGM until the expiration of the term of the current session of the Board. Her remuneration will be determined by the Board and the Remuneration Committee with reference to her duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Dr. He does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications. She does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. She does not have any relationship with other Directors, Supervisors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules.

Save as disclosed above, Dr. He has met the independence criteria set out in Rule 5.09 of the GEM Listing Rules and there are no other matters relating to her appointment that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

The Company has fulfilled the gender diversity requirement under Rule 17.104 of GEM Listing Rules following her appointment.

The Board wishes to take this opportunity to welcome Dr. He for joining the Board.

### **(III) CHANGE OF SUPERVISOR**

As disclosed in the Resignation Announcement, the resignation of Mr. Li as a Supervisor and the chairman of the Supervisory Committee will take effect after the election of a new Supervisor at a general meeting to be convened and held by the Company.

Mr. Li has confirmed that he has no disagreement with the Board and the Supervisory Committee and there are no other matters relating to his resignation as a Supervisor that need to be brought to the attention of the Shareholders.

The Board and the Supervisory Committee would like to express their sincere gratitude to Mr. Li for his contributions to the Company during his tenure.

The Board also announces that Mr. Fan has been appointed to replace Mr. Li as a Supervisor with effect from 28 June 2024 following the approval of his appointment by the Shareholders at the AGM. Upon his appointment as a Supervisor, Mr. Fan will also act as the chairman of the Supervisory Committee.

Biographical details of Mr. Fan are as follows:

**Mr. FAN Hua (范華先生)**, aged 60, graduated in Accounting Profession from Sichuan Radio and TV University (currently named as The Open University of Sichuan) in 1986 and is a Certified Public Accountant of the PRC. He has been engaged in finance and management works for more than 30 years and is currently the general manager of Sichuan Guoke Kangyi Medical Technology Co., Ltd.\* (四川國科康儀醫療科技有限公司).

Mr. Fan will enter into a service agreement with the Company. His term of service with the Company takes effect from the date of approval by the Shareholders at the AGM until the expiration of the term of the current session of the Supervisory Committee. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Fan does not hold any directorship in other publicly listed company in Hong Kong or overseas in the last three years nor any other position with the Company or other members of the Group. In addition, he does not have any relationship with other Directors, Supervisors, senior management or substantial or controlling shareholders of the Company, nor has any interests in the Shares within the meaning of Part XV of the SFO. There is no other information which is discloseable, nor is/was he involved in any of the matters required to be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules. There is no other matter in relation to the proposed appointment of Mr. Fan as a Supervisor that needs to be brought to the attention of the Shareholders.

The Board wishes to take this opportunity to welcome Mr. Fan for joining the Company.

\* *For identification purposes only.*

For and on behalf of the Board  
**Biosino Bio-Technology and Science Incorporation**  
**Wu Lebin**  
*Chairman and Executive Director*

Beijing, the PRC, 28 June 2024

As at the date of this announcement, the Board comprises:

*Chairman and executive Director*

Mr. Wu Lebin (吳樂斌先生)

*Vice chairmen and non-executive Directors*

Mr. Yang Peng (楊鵬先生) and Mr. Chen Zhengyong (陳正永先生)

*President and executive Director*

Mr. Chen Peng (陳鵬先生)

*Non-executive Directors*

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

*Independent non-executive Directors*

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生), Prof. Shen Jiangang (沈劍剛教授) and Dr. He Xin (何欣博士)

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its posting and on the website of the Company at [www.zhongsheng.com.cn](http://www.zhongsheng.com.cn).*